SELEX

SELEX (Systematic Evolution of Ligands by Exponential Enrichment, where selected winners amplify during the PCR growth phase as N(c) = N₀·e^*r*·*c*; also known as in vitro selection or in vitro evolution) is a combinatorial molecular biology technique that isolates single-stranded ribonucleic acid (RNA), deoxyribonucleic acid (DNA), or xeno-nucleic acid (XNA) oligomers capable of high-affinity ligand binding (aptamers) or enzymatic catalysis (ribozymes and deoxyribozymes) from large random-sequence pools. Invented independently in 1990 by three laboratories—Craig Tuerk and Larry Gold at the University of Colorado Boulder (selecting RNA ligands for bacteriophage T4 gp43 DNA polymerase), Andrew D. Ellington and Jack W. Szostak at Massachusetts General Hospital (coining the term aptamer for organic-dye-binding RNAs), and Debra L. Robertson and Gerald F. Joyce at Scripps Research Institute (evolving a Tetrahymena ribozyme variant that cleaves single-stranded DNA)—SELEX applies Darwinian variation, phenotypic partitioning, and amplification to nucleic acid populations in a test tube.

By sampling 10¹⁴ to 10¹⁶ sequences in a single microcentrifuge reaction, SELEX explores sequence space beyond the genomic capacity of living organisms. In origin-of-life research, SELEX provided experimental verification of the RNA world by demonstrating that random RNA pools harbor catalysts for nucleotide synthesis, RNA polymerization, aminoacylation, peptide bond formation, and carbon–carbon bond formation. In medicine and biotechnology, SELEX has yielded FDA-approved therapeutic aptamers, biosensors, and proteomic capture arrays.

Combinatorial Library Synthesis and Sequence Space Sampling

Every SELEX experiment begins with the solid-phase phosphoramidite chemical synthesis of a single-stranded DNA oligonucleotide library (60 to 120 nucleotides in length). The library architecture comprises a central randomized core region of N = 20 to 80 nucleotides—synthesized by pulsing an equimolar mixture of all four phosphoramidite monomers (dA, dC, dG, dT) at each coupling step—flanked on the 5' and 3' ends by fixed 18- to 25-nucleotide primer-binding sequences (including a 5' bacteriophage T7 promoter when transcribing RNA libraries).

For a randomized region of length N, the theoretical genotype space is 4^N. When N = 25, 4²⁵ ≈ 1.1 × 10¹⁵ possible sequences exist, meaning a standard 1–2 nanomole synthesis (~6 × 10¹⁴ to 1.2 × 10¹⁵ molecules) samples nearly every possible 25-mer sequence. For longer random cores such as N = 40 (4⁴⁰ ≈ 1.2 × 10²⁴) or N = 70 (4⁷⁰ ≈ 1.4 × 10⁴²), a 10¹⁵-molecule starting pool sparsely samples sequence space, relying on neutral structural neighborhoods (RNA hairpins, bulges, pseudoknots, and G-quadruplexes) and mutagenic PCR diversification during later rounds to climb fitness peaks.

Partitioning, Amplification, and Conditioning Across Rounds

Once the starting DNA pool is transcribed into single-stranded RNA via T7 RNA polymerase (or used directly for DNA/XNA selection), SELEX proceeds through five cyclic steps repeated across 6 to 20 rounds:

1. Incubation and Folding: The single-stranded library is heated and cooled in buffer containing divalent cations (1–10 mM Mg²⁺ and 100–150 mM Na⁺/K⁺) to fold into three-dimensional structures, then incubated with the target ligand or substrate.
2. Partitioning (Selection): Active sequences are separated from inactive bulk sequences using affinity chromatography, paramagnetic beads, nitrocellulose filters, capillary electrophoresis (CE-SELEX), or live cells (Cell-SELEX), alongside counter-selection against support matrices. In catalytic selections, active ribozymes covalently attach a biotin tag or cleave themselves off a solid support.
3. Elution and Recovery: Target-bound aptamers or self-modified ribozymes are eluted using denaturants (7 M urea, EDTA), ligand competition, or heat.
4. Amplification: Recovered RNA sequences are reverse-transcribed into cDNA and amplified via PCR or RT-PCR (optionally with Mn²⁺ error-prone mutagenesis at 0.5%–2% per base).
5. Conditioning: Double-stranded PCR amplicons are transcribed back into single-stranded RNA by T7 RNA polymerase (or strand-separated on streptavidin beads) to initiate the next selection round under higher stringency.

Synthetic Ribozymes Evolved by SELEX

Prior to 1990, known natural ribozymes (outside the later-resolved ribosome peptidyl transferase center) catalyzed only phosphorus–oxygen transesterification or hydrolysis. SELEX demonstrated that RNA can catalyze diverse metabolic reactions:

• Class I RNA Ligase and Replicases: In 1993, David P. Bartel and Jack W. Szostak isolated the Class I ligase ribozyme from 1.6 × 10¹⁵ random 220-nt RNAs (~10⁹-fold rate acceleration), which became the progenitor of evolved RNA replicase ribozymes (R18, tC19Z, 24-3).
• Aminoacylation and Flexizymes: Michael Yarus and Hiroaki Suga used SELEX to evolve tRNA-charging ribozymes, culminating in Suga's 45-nt flexizymes (eFx, dFx, aFx).
• Metabolic Bond Formation: Zhang and Cech (1997) evolved peptide-bond-forming ribozymes; Unrau and Bartel (1998) evolved pyrimidine nucleotide synthase ribozymes; and Tarasow, Eaton, and Jäschke evolved carbon–carbon bond-forming Diels–Alderase and NAD⁺-dependent redox ribozymes.

Therapeutic Aptamers and SOMAmer Proteomics

To prevent serum RNase degradation and renal clearance in vivo, clinical aptamers incorporate 2'-fluoro (2'-F) and 2'-O-methyl (2'-OMe) nucleotides, 3'-inverted dT caps, and 40-kDa polyethylene glycol (PEG) tails. FDA-approved SELEX drugs include pegaptanib (Macugen, 2004), a 28-nt anti-VEGF₁₆₅ aptamer (K_d = 49 pM) for wet macular degeneration, and avacincaptad pegol (Izervay, 2023), a 39-nt anti-complement C5 aptamer for geographic atrophy. At SomaLogic, Larry Gold developed SOMAmers bearing hydrophobic C5-dUTP side chains to quantify >10,000 human plasma proteins.

How many sequences can a single SELEX library test at once, and what fraction of sequence space is covered?

A standard laboratory SELEX library contains 1 to 10 nanomoles of synthesized DNA, which corresponds to roughly 6 × 10¹⁴ to 6 × 10¹⁵ individual molecules in a microcentrifuge tube. Because there are 4^N possible sequences of length N, a library with a 25-nucleotide randomized region (4²⁵ ≈ 1.1 × 10¹⁵) covers nearly 100% of all possible sequences. For a 40-nucleotide random region (4⁴⁰ ≈ 1.2 × 10²⁴), the initial pool samples about 1 in 10⁹ possible sequences, relying on mutagenic PCR in subsequent rounds to optimize functional motifs.

How did SELEX prove the catalytic plausibility of the RNA World hypothesis?

Before the invention of SELEX in 1990, critics of the RNA World hypothesis argued that natural ribozymes (like Group I introns and RNase P) only catalyze phosphorus–oxygen bond cleavage and ligation, suggesting RNA lacked the chemical versatility to run a cellular metabolism. Using SELEX to screen 10¹⁵ random RNA molecules, researchers evolved artificial ribozymes that catalyze template-directed RNA polymerization, tRNA aminoacylation (flexizymes), peptide bond synthesis, glycosidic nucleotide synthesis, NAD⁺-dependent redox reactions, and Diels–Alder carbon–carbon bond formation, proving that RNA can accelerate diverse metabolic reactions.

Why are chemical modifications needed to turn SELEX aptamers into human drugs?

Unmodified RNA aptamers contain a 2'-hydroxyl group on every ribose ring, making them targets for abundant pancreatic-type ribonucleases (such as RNase A) in human blood, which cleave unmodified RNA within seconds to minutes. Furthermore, because a 25–40 nucleotide aptamer has a molecular weight of only 8 to 13 kDa—well below the ~30–50 kDa glomerular filtration cutoff of the kidney—it is cleared into urine. Therapeutic aptamers like pegaptanib and avacincaptad pegol replace 2'-OH groups with nuclease-resistant 2'-fluoro and 2'-O-methyl groups and attach a 40-kDa polyethylene glycol (PEG) tail.

1. Tuerk, C., & Gold, L. (1990). "Systematic evolution of ligands by exponential enrichment (exp(*r*·*t*) growth phase): RNA ligands to bacteriophage T4 DNA polymerase." Science, 249(4968), 505–510. https://doi.org/10.1126/science.2200121
2. Ellington, A. D., & Szostak, J. W. (1990). "In vitro selection of RNA molecules that bind specific ligands." Nature, 346(6287), 818–822. https://doi.org/10.1038/346818a0
3. Robertson, D. L., & Joyce, G. F. (1990). "Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA." Nature, 344(6265), 467–468. https://doi.org/10.1038/344467a0
4. Bartel, D. P., & Szostak, J. W. (1993). "Isolation of new ribozymes from a large pool of random sequences." Science, 261(5127), 1411–1418. https://doi.org/10.1126/science.7690155